Skip to main content

Advertisement

SpringerLink
Log in

The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a lifelong strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short- and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α-reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α-blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Wei JT, Calhoun E, Jacobsen SJ: Urologic disease in America project: benign prostatic hyperplasia. J Urol 2005, 173:1256–1261. An important analysis of the annual costs of medical therapy for BPH.

    Article  PubMed  Google Scholar 

  2. Chapple CR: Selective 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996, 29:129–144.

    PubMed  CAS  Google Scholar 

  3. MacDonald D, McNicholas TA: Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life. Drugs 2003, 63:1947–1962.

    Article  PubMed  CAS  Google Scholar 

  4. Carbone DJ Jr, Hodges S: Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 2003, 15:299–306.

    Article  PubMed  Google Scholar 

  5. McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398. The largest, longest, most important clinical trial undertaken by a nonpharmaceutical research group to determine the long-term effects of medical therapy for BPH.

    Article  PubMed  CAS  Google Scholar 

  6. AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530–547. This most recent update of the 1994 BPH guidelines critically examines and analyzes the data from all clinical trials available to provide guidelines for the management of BPH based on best available evidence.

    Article  Google Scholar 

  7. Chrischilles E, Rubenstein L, Chao J, et al.: Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. Clin Ther 2001, 23:727–743.

    Article  PubMed  CAS  Google Scholar 

  8. Hillman AL, Schwartz JS, Willian MK, et al.: The costeffectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996, 47:169–178.

    Article  PubMed  CAS  Google Scholar 

  9. Berges RS: Impact of therapy used in clinical practice on lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) disease progression. Eur Urol 2003, 2(suppl):19–24.

    CAS  Google Scholar 

  10. de la Rosette JJ, Kortman BB, Rossi C, et al.: Long-term risk of re-treatment of patients using-blockers for lower urinary tract symptoms. J Urol 2002, 167:1734–1739.

    Article  PubMed  Google Scholar 

  11. Ohsfeldt RL, Kreder KJ, Klein RW, Chrischilles EA: Costeffectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. J Manag Care Pharm 2004, 10:412–422.

    PubMed  Google Scholar 

  12. Nickel JC: Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004, 6(suppl 9):31–39.

    Google Scholar 

  13. Cockrum PC, Finder SF, Ries AJ, Potyk RP: A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. Pharmacoeconomics 1997, 11:550–565.

    PubMed  CAS  Google Scholar 

  14. Baladi JF, Menon D, Otten N: An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics 1996, 9:443–454.

    Article  PubMed  CAS  Google Scholar 

  15. McConnell JD, Bruskewitz R, Walsh P: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338:557–563.

    Article  PubMed  CAS  Google Scholar 

  16. McDonald H, Hux M, Brisson M, et al.: An economic evaluation of doxazosin, finasteride, and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol 2004, 11:2327–2340. A comprehensive assessment employing a semi-Markov decision analytical model of the costs and cost-utility (QALY gained) for finasteride and combination therapy employing data from PLESS (reference 15) and MTOPS (reference 5)

    PubMed  Google Scholar 

  17. Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146:473–481.

    PubMed  CAS  Google Scholar 

  18. Roehrborn CG, Boyle P, Bergner D, et al.: Serum prostatespeci fic antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999, 54:662–669.

    Article  PubMed  CAS  Google Scholar 

  19. Roehrborn CG, McConnell JD, Bonilla J, et al.: Serum prostate-specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR Long-term Efficacy and Safety Study. J Urol 2000, 163:13–20.

    Article  PubMed  CAS  Google Scholar 

  20. Roehrborn CG, Malde M, Cook TJ, et al.: Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001, 58:210–216.

    Article  PubMed  CAS  Google Scholar 

  21. Albertsen PC, Pellissier JM, Lowe FC, et al.: Economic analysis of finasteride: a model-based approach using data from the Proscar Long-term Efficacy and Safety Study. Clin Ther 1999, 21:1006–1024.

    Article  PubMed  CAS  Google Scholar 

  22. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC:Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001, 58:203–209.

    Article  PubMed  CAS  Google Scholar 

  23. Barkin J, Guimaraes M, Jacobi G, et al.: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha-reductase inhibitor dutasteride. Eur Urol 2003, 44:461–466.

    Article  PubMed  CAS  Google Scholar 

  24. Jepsen JV, Bruskewitz RC: Surgical and nonsurgical invasive treatment of benign prostatic hyperplasia. Drugs Today (Barc) 1998, 34:353–360.

    CAS  Google Scholar 

  25. Blute M, Ackerman SJ, Rein AL, et al.: Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia. Part II: results. Urology 2000, 56:981–987.

    Article  PubMed  CAS  Google Scholar 

  26. Jepsen JV, Bruskewitz RC: Economics of transurethral thermotherapy of the prostate. World J Urol 1998, 16:138–141.

    Article  PubMed  CAS  Google Scholar 

  27. Naslund MJ, Carlson AM, Williams MJ: A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period. J Urol 2005, 173:2090–2093.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Queen’s University, Kingston General Hospital, K7L 2V7, Kingston, Ontario, Canada

    J. Curtis Nickel MD

Authors
  1. J. Curtis Nickel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Curtis Nickel MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nickel, J.C. The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Curr Urol Rep 7, 282–287 (2006). https://doi.org/10.1007/s11934-996-0007-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-996-0007-z

Keywords

Search

Navigation